Cross-Sector entity
JAMA Internal Medicine is most often covered alongside 2024-2025 COVID-19 Vaccine, which appears in 2 of these 2 stories. The clearest coverage concentration is clinical-trial: 1 of 2 stories, with the rest divided among 1 other category. Each carries 4 original sources on average.
2 verified stories tracked
Last mentioned: Jun 28, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
JAMA Internal Medicine is most often covered alongside 2024-2025 COVID-19 Vaccine, which appears in 2 of these 2 stories. The clearest coverage concentration is clinical-trial: 1 of 2 stories, with the rest divided among 1 other category. Each carries 4 original sources on average. We currently track 2 Cross-Sector stories that mention JAMA Internal Medicine, all published on June 28, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering JAMA Internal Medicine. Shared-story counts are live from our verified record — not editorial picks.
A massive Veterans Affairs study of over one million veterans reveals the 2024-2025 COVID vaccine significantly reduces cardiovascular events, especially in older adults, offering healthcare systems a new preventive tool.
The 2024-2025 COVID vaccine reduced MACE by 37.7% in a large VA trial, with even greater benefits in high-risk subgroups, sparking biopharma interest in a cardiovascular indication for mRNA vaccines.
Source: wtag.iheart.com · wrno.iheart.com
